🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 19 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 16/01/2002 | 22,12 | 22,90 | 21,34 | 21,44 | -4,33% | 7,05% | 802.700 |
| 15/01/2002 | 22,26 | 22,95 | 21,59 | 22,41 | +0,04% | 6,11% | 807.300 |
| 14/01/2002 | 23,80 | 23,82 | 22,04 | 22,40 | -5,72% | 7,48% | 1.132.300 |
| 11/01/2002 | 23,60 | 24,48 | 23,47 | 23,76 | +0,81% | 4,28% | 980.100 |
| 10/01/2002 | 23,40 | 24,19 | 22,91 | 23,57 | +1,33% | 5,47% | 832.800 |
| 09/01/2002 | 23,27 | 24,21 | 23,12 | 23,26 | -0,09% | 4,68% | 794.400 |
| 08/01/2002 | 23,59 | 24,05 | 23,14 | 23,28 | -2,14% | 3,86% | 540.100 |
| 07/01/2002 | 24,81 | 25,40 | 23,57 | 23,79 | -0,67% | 7,38% | 724.700 |
| 04/01/2002 | 24,30 | 25,00 | 22,99 | 23,95 | -0,91% | 8,27% | 1.199.400 |
| 03/01/2002 | 24,58 | 24,66 | 23,23 | 24,17 | -1,51% | 5,82% | 1.154.800 |
| 02/01/2002 | 24,86 | 24,89 | 23,24 | 24,54 | -0,20% | 6,64% | 627.800 |
| 31/12/2001 | 25,44 | 25,54 | 23,77 | 24,59 | -3,72% | 6,96% | 652.900 |
| 28/12/2001 | 24,66 | 25,90 | 24,62 | 25,54 | +3,44% | 5,19% | 624.000 |
| 27/12/2001 | 23,85 | 24,98 | 23,85 | 24,69 | +3,00% | 4,74% | 788.800 |
| 26/12/2001 | 23,30 | 24,64 | 22,76 | 23,97 | +3,81% | 8,07% | 624.900 |
| 24/12/2001 | 23,25 | 23,50 | 23,09 | 23,09 | +0,79% | 1,76% | 283.200 |
| 21/12/2001 | 21,76 | 23,26 | 21,76 | 22,91 | +2,51% | 6,89% | 977.300 |
| 20/12/2001 | 22,44 | 23,42 | 22,26 | 22,35 | -0,71% | 5,17% | 975.000 |
| 19/12/2001 | 23,86 | 23,99 | 22,36 | 22,51 | -5,78% | 6,83% | 1.168.000 |
| 18/12/2001 | 24,60 | 25,20 | 23,51 | 23,89 | -2,41% | 6,87% | 725.700 |
| 17/12/2001 | 23,68 | 24,94 | 23,51 | 24,48 | +1,41% | 6,04% | 459.000 |
| 14/12/2001 | 24,79 | 25,13 | 23,58 | 24,14 | -2,46% | 6,25% | 510.100 |
| 13/12/2001 | 23,98 | 25,70 | 23,50 | 24,75 | +1,85% | 9,17% | 785.500 |
| 12/12/2001 | 24,54 | 24,77 | 22,95 | 24,30 | +0,16% | 7,42% | 667.700 |
| 11/12/2001 | 25,47 | 25,50 | 23,83 | 24,26 | -1,46% | 6,56% | 879.300 |
| 10/12/2001 | 27,25 | 27,25 | 24,42 | 24,62 | -9,78% | 10,39% | 809.900 |
| 07/12/2001 | 27,30 | 27,81 | 26,81 | 27,29 | -0,87% | 3,66% | 563.400 |
| 06/12/2001 | 26,99 | 28,84 | 26,91 | 27,53 | +2,15% | 7,15% | 1.205.300 |
| 05/12/2001 | 25,70 | 27,24 | 25,68 | 26,95 | +6,27% | 6,07% | 1.508.100 |
| 04/12/2001 | 24,86 | 25,69 | 24,68 | 25,36 | +2,80% | 4,06% | 1.606.800 |